We only have this paper's title and publication details.
Read it at the sourceExpert commentary reviews clinical evidence from the RASolute 302 trial in advanced pancreatic cancer, highlighting critical hurdles and future strategies for targeting oncogenic RAS signaling.
No takes yet. Share an insight, caveat, or question.
Andrew H. Ko (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: